RELIEF THERAPEUTICS Holding (RLFTF) Price & Analysis

Compare

305 Followers

RLFTF Stock Chart & Stats

$1.88

$0.00(0.00%)

At close: Jan 07 4:00 PM EST

$1.88

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$1.29 - $4.88

Previous CloseN/A

Volume114.00

Average Volume (3M)3.53K

Market Cap

$238.11M

Enterprise Value$16.26M

Total Cash (Recent Filing)$12.50M

Total Debt (Recent Filing)$1.90M

Price to Earnings (P/E)―

Beta-0.16

Next Earnings

Apr 09, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.45

Shares Outstanding159,102,450

10 Day Avg. Volume4,412

30 Day Avg. Volume3,527

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)1.44

Price to Sales (P/S)6.27

P/FCF Ratio-17.10

Enterprise Value/Market Cap0.07

Enterprise Value/Revenue4.01

Enterprise Value/Gross Profit-13.82

Enterprise Value/Ebitda-0.89

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Gross MarginA gross margin of ~69% provides a durable structural cushion versus peers, implying product or cost advantages on core offerings. Sustained high gross margins give management flexibility to invest in R&D and commercialization while dampening the revenue growth needed to approach operating profitability over time.

Very Low Financial LeverageExtremely low leverage and a strong equity ratio reduce solvency risk and preserve strategic optionality through clinical cycles. This structural balance-sheet strength supports access to capital, strategic partnerships, and cushioning against development setbacks without urgent refinancing pressure.

Diversified Revenue/funding ModelA business model that includes licensing, milestone payments, royalties, and grants distributes commercial risk and provides non-dilutive funding pathways. Structurally, this reduces dependency on product sales timing and enables capital-efficient advancement of the pipeline through partnerships and staged payments.

Bears Say

Persistent Negative ProfitabilityOngoing net losses and negative operating margins indicate the core business is not yet self-sustaining. Over the medium term the company must either achieve sustained positive operating leverage or secure repeated external funding, otherwise cash burn will constrain R&D and commercialization plans.

Negative Free Cash FlowNegative free cash flow limits the firm's ability to internally fund trials and commercialization costs, forcing reliance on equity or partnership financing. While improvement is positive, durable operational health requires consistent positive FCF to reduce dilution risk and finance long-term growth.

Unprofitable With No Dividend SupportBeing unprofitable removes earnings-derived resilience and eliminates dividend income as investor support. Structurally this heightens dependence on capital markets and strategic deals for runway, increasing dilution and execution risk if clinical or commercialization milestones slip.

RELIEF THERAPEUTICS Holding News

MindMaze Sets Global Reimbursement Framework to Scale AI-Powered Neurorehabilitation

RELIEF THERAPEUTICS Holding ( ($CH:MMTX) ) has issued an update. MindMaze Therapeutics has detailed a coordinated global reimbursement...

1M ago

Relief Therapeutics and NeuroX Merge to Form MindMaze Therapeutics

An announcement from RELIEF THERAPEUTICS Holding ( ($CH:RLF) ) is now available. Relief Therapeutics and NeuroX have completed...

2M ago

Relief Therapeutics and NeuroX Announce Strategic Business Combination

RELIEF THERAPEUTICS Holding ( ($CH:RLF) ) just unveiled an update. Relief Therapeutics Holding SA announced a joint presentation...

2M ago

Relief Therapeutics to Merge with NeuroX, Forming MindMaze Therapeutics

RELIEF THERAPEUTICS Holding ( ($CH:RLF) ) has shared an update. Relief Therapeutics Holding SA announced that its shareholders...

3M ago

Relief Therapeutics Reports Positive Bioequivalence Study Results for PKU Treatment

An update from RELIEF THERAPEUTICS Holding ( ($CH:RLF) ) is now available. Relief Therapeutics announced positive results from...

3M ago

Relief Therapeutics Plans Strategic Merger with NeuroX Group

The latest update is out from RELIEF THERAPEUTICS Holding ( ($CH:RLF) ). Relief Therapeutics has announced an extraordinary...

3M ago

Relief Therapeutics and NeuroX Merge to Form AI-Driven Health Tech Leader

RELIEF THERAPEUTICS Holding ( ($CH:RLF) ) has shared an announcement. Relief Therapeutics and NeuroX have signed a definitive...

4M ago

Relief Therapeutics Advances Pipeline and Explores AI-driven Expansion

RELIEF THERAPEUTICS Holding ( ($CH:RLF) ) just unveiled an update. Relief Therapeutics has released its 2025 half-year report,...

6M ago

Relief Therapeutics Advances 2025 Half-Year Report Publication

An announcement from RELIEF THERAPEUTICS Holding ( ($CH:RLF) ) is now available. Relief Therapeutics has announced an advancement...

6M ago

Relief Therapeutics to Merge with NeuroX, Expanding AI-Driven Health Tech Platform

RELIEF THERAPEUTICS Holding ( ($CH:RLF) ) has provided an announcement. Relief Therapeutics has announced a proposed business combination...

6M ago

Relief announces results of annual general meeting

RELIEF THERAPEUTICS announces the results of its annual general meeting of shareholders, which took place in Geneva. All...

2y ago

Acer Therapeutics, Relief announce FDA approval of Olpruva

Acer Therapeutics (ACER) and its collaboration partner, Relief (RLFTF) announced that the FDA has approved Olpruva for oral...

3y ago

ACER

RLFTF FAQ

What was RELIEF THERAPEUTICS Holding’s price range in the past 12 months?

RELIEF THERAPEUTICS Holding lowest stock price was $1.29 and its highest was $4.88 in the past 12 months.

What is RELIEF THERAPEUTICS Holding’s market cap?

RELIEF THERAPEUTICS Holding’s market cap is $238.11M.

When is RELIEF THERAPEUTICS Holding’s upcoming earnings report date?

RELIEF THERAPEUTICS Holding’s upcoming earnings report date is Apr 09, 2026 which is in 63 days.

How were RELIEF THERAPEUTICS Holding’s earnings last quarter?

RELIEF THERAPEUTICS Holding released its earnings results on Aug 29, 2025. The company reported -$0.449 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.449.

Is RELIEF THERAPEUTICS Holding overvalued?

According to Wall Street analysts RELIEF THERAPEUTICS Holding’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does RELIEF THERAPEUTICS Holding pay dividends?

RELIEF THERAPEUTICS Holding does not currently pay dividends.

What is RELIEF THERAPEUTICS Holding’s EPS estimate?

RELIEF THERAPEUTICS Holding’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does RELIEF THERAPEUTICS Holding have?

RELIEF THERAPEUTICS Holding has 159,102,450 shares outstanding.

What happened to RELIEF THERAPEUTICS Holding’s price movement after its last earnings report?

RELIEF THERAPEUTICS Holding reported an EPS of -$0.449 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.149%.

Which hedge fund is a major shareholder of RELIEF THERAPEUTICS Holding?

Currently, no hedge funds are holding shares in RLFTF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

RELIEF THERAPEUTICS Holding

MindMaze Therapeutics Holding SA develops and operates the MindMaze platform that integrates neuroscience and digital therapeutics to address some of the most pressing challenges in neurology. MindMaze Therapeutics Holding SA was formerly known as NeuroX Group SA. The company was incorporated in 2025 and is based in Lausanne, Switzerland.